Table 3.
The plasma pharmacokinetics of budesonide at steady-state following once daily administration of MMX®-budesonide tablets containing 9 mg of the drug for 7 days. Results are presented as means ± SD, n = 12
| Mean ± SD | Max | Min | CV% | |
|---|---|---|---|---|
| Cssmin | 109.9 ± 75.3 | 269.4 | 0 | 68.5 |
| Cssmax | 891.3 ± 294.1 | 1433.5 | 158 | 44.2 |
| tssmax | 11 ± 4.9 | 16 | 0 | 44.9 |
| Caverage | 387.3 ± 153.9 | 607.8 | 82.4 | 39.7 |
| AUCss | 9295.2 ± 3694.2 | 14588 | 1978.5 | 39.7 |
| %PTF | 205.9 ± 83.9 | 412.5 | 128.5 | 40.7 |
Cssmin, minimum plasma concentration at steady state; Cssmax, maximum plasma concentration at steady state; tssmax, time at which Cssmax is achieved; Caverage, mean or average steady state drug concentration; AUCss, area under the concentration/time curve during the selected dosing; interval at steady state calculated with trapezoidal method; %PTF, peak-through- fluctuation percentage.